MacroGenics Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobra
MacroGenics presented updated efficacy and safety results from the TAMARACK Phase 2 study of vobramitamab duocarmazine (vobra duo) for mCRPC at ESMO, showing encouraging antitumor activity with 6-month landmark rPFS rates of 69% and 70% in the 2.0 mg/kg and 2.7 mg/kg arms, respectively. Patients remained on vobra duo through a median of 6 doses, and the company expects mature median rPFS data no later than early 2025.
Reference News
MacroGenics presented updated efficacy and safety results from the TAMARACK Phase 2 study of vobramitamab duocarmazine (vobra duo) for mCRPC at ESMO, showing encouraging antitumor activity with 6-month landmark rPFS rates of 69% and 70% in the 2.0 mg/kg and 2.7 mg/kg arms, respectively. Patients remained on vobra duo through a median of 6 doses, and the company expects mature median rPFS data no later than early 2025.